Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.

LENSAR, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

18 ALLY ROBOTIC CATARACT LASER SYSTEMS (ALLY SYSTEMS) PLACED IN 2Q 2025 WITH AN ADDITIONAL BACKLOG OF 18 ALLY SYSTEMS PENDING INSTALLATION AS OF JUNE 30, 2025

LENSAR REPORTS SECOND QUARTER 2025 RESULTS AND PROVIDES BUSINESS UPDATE

ORLANDO, FLA., JULY 01, 2025 (GLOBE NEWSWIRE) -- LENSAR, INC.(NASDAQ: LNSR) (LENSAR OR THE COMPANY) TODAY ANNOUNCED THAT A MAJORITY OF THE INDEPENDENT MEMBERS OF LENSAR'S BOARD OF DIRECTORS GRANTED THREE NEWLY-HIRED NON-EXECUTIVE EMPLOYEES AN AGGREGATE OF 660 RESTRICTED STOCK UNITS (RSUS). THE RSUS WERE GRANTED AS OFJULY 1, 2025, AS INDUCEMENT FOR EACH SUCH EMPLOYEE COMMENCING EMPLOYMENT WITH THE COMPANY. THE RSUS WERE GRANTED IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

LENSAR REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF LENSAR, INC. (NASDAQCM: LNSR) TO ALCON INC. (NYSE: ALC). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF LENSAR WILL RECEIVE $14.00 IN CASH, WITH AN ADDITIONAL NON-TRADEABLE CONTINGENT VALUE RIGHT OFFERING UP TO $2.75 PER SHARE IN CASH CONDITIONED ON ACHIEVEMENT OF A MILESTONE, FOR EACH.

LENSAR INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF LENSAR, INC. - LNSR

ORLANDO, FLA., JUNE 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, INC.(NASDAQ: LNSR) (LENSAR OR THE COMPANY) TODAY ANNOUNCED THAT A MAJORITY OF THE INDEPENDENT MEMBERS OF LENSAR'S BOARD OF DIRECTORS GRANTED 10 NEWLY-HIRED NON-EXECUTIVE EMPLOYEES AN AGGREGATE OF 3,090 RESTRICTED STOCK UNITS (RSUS). THE RSUS WERE GRANTED AS OFJUNE 2, 2025, AS INDUCEMENT FOR EACH SUCH EMPLOYEE COMMENCING EMPLOYMENT WITH THE COMPANY. THE RSUS WERE GRANTED IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

14 ALLY ROBOTIC LASER CATARACT SYSTEMS (ALLY SYSTEMS) PLACED IN 1Q 2025 WITH AN ADDITIONAL BACKLOG OF 24 SYSTEMS PENDING INSTALLATION AS OF MARCH 31, 2025

LENSAR REPORTS FIRST QUARTER 2025 RESULTS AND PROVIDES BUSINESS UPDATE

ORLANDO, FLA., MARCH 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, INC.(NASDAQ: LNSR) (LENSAR OR THE COMPANY) TODAY ANNOUNCED THAT A MAJORITY OF THE INDEPENDENT MEMBERS OF LENSAR'S BOARD OF DIRECTORS GRANTED TWO NEWLY-HIRED NON-EXECUTIVE EMPLOYEES STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 1,600 SHARES OF THE COMPANY'S COMMON STOCK. THE OPTIONS WERE GRANTED AS OFMARCH 3, 2025, AS INDUCEMENTS MATERIAL TO EACH EMPLOYEE ENTERING INTO EMPLOYMENT WITH THE COMPANY. THE OPTIONS WERE GRANTED IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

31 ALLY ROBOTIC CATARACT LASER SYSTEMS PLACED IN Q4 2024, REPRESENTING AN 86% INCREASE IN ALLY PLACEMENTS IN FULL YEAR 2024 OVER 2023; COMPANY'S TOTAL INSTALLED SYSTEMS INCREASED TO APPROXIMATELY 385 AS OF DECEMBER 31, 2024, REPRESENTING A 26% INCREASE OVER 2023 FOURTH QUARTER 2024 REVENUE INCREASED 38% OVER FOURTH QUARTER 2023; FULL-YEAR REVENUE INCREASED 27% OVER 2023 RECURRING REVENUE EXCEEDS $40 MILLION FOR THE FULL YEAR; INCREASED 23% OVER 2023 ORLANDO, FLA., FEB. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, INC. (NASDAQ: LNSR) (LENSAR OR THE COMPANY), A GLOBAL MEDICAL TECHNOLOGY COMPANY FOCUSED ON ADVANCED ROBOTIC LASER SOLUTIONS FOR THE TREATMENT OF CATARACTS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2024 AND PROVIDED AN UPDATE ON KEY OPERATIONAL INITIATIVES.

LENSAR REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS AND PROVIDES BUSINESS UPDATE

ORLANDO, FLA., FEB. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, INC. (NASDAQ: LNSR) (LENSAR OR THE COMPANY), A GLOBAL MEDICAL TECHNOLOGY COMPANY FOCUSED ON ADVANCED ROBOTIC LASER SOLUTIONS FOR THE TREATMENT OF CATARACTS, TODAY ANNOUNCED THAT THE COMPANY'S FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS WILL BE RELEASED BEFORE MARKET OPEN ON THURSDAY, FEBRUARY 27, 2025. LENSAR'S MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:30 AM ET ON THURSDAY, FEBRUARY 27, 2025 TO DISCUSS THE FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.

LENSAR TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ON THURSDAY, FEBRUARY 27, 2025

ORLANDO, FLA., FEB. 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, INC.(NASDAQ: LNSR) (LENSAR OR THE COMPANY) TODAY ANNOUNCED THAT A MAJORITY OF THE INDEPENDENT MEMBERS OF LENSAR'S BOARD OF DIRECTORS GRANTED TWO NEWLY-HIRED NON-EXECUTIVE EMPLOYEES STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 875 SHARES OF THE COMPANY'S COMMON STOCK. THE OPTIONS WERE GRANTED AS OFFEBRUARY 3, 2025, AS INDUCEMENTS MATERIAL TO EACH EMPLOYEE ENTERING INTO EMPLOYMENT WITH THE COMPANY. THE OPTIONS WERE GRANTED IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

LENSAR, Inc.

LNSR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LENSAR, Inc.

LNSR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LNSR